Clinical trials: 5-FU
Metastatic Pancreatic Adenocarcinoma
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.
MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease controlled after 4 months of mFOLFIRINOX…
- Trial name
- MAZEPPA (NCT04348045)
- Testing
- Arm A - Olaparib, ARM B - durvalumab plus selumetinib, ARM C FOLFIRI
- Where
- 29 sites in France
- Volunteers
- 307 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Squamous Cell Carcinoma of the Head and Neck
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN）
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03855384
- Testing
- TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
- Where
- China
- Volunteers
- 334 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colon Cancer, Colon Cancer (Stage II &Amp;Amp;Amp; III)
ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study
The goal of this clinical trial is to explore the disease-free survival period of elderly patients with high-risk stage II and stage III colon cancer based on ctDNA detection.
- Trial name
- ZJCH-CRCC-1 (NCT06609551)
- Testing
- 6-month adjuvant chemotherapy with 5-FU monotherapy, XELOX intensive treatment group
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Zhejiang Cancer Hospital
BRAF V600 Colorectal Cancer
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if Iparomlimab and Tuvonralimab combined with bevacizumab and FOLFIRI (IB-FOLFIRI) is safe and effective in treating adults with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
- Trial name
- NCT07150247
- Testing
- Iparomlimab and Tuvonralimab, Bevacizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Adenocarcinoma of the Colon, Stage III Colon Cancer
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003835
- Testing
- leucovorin calcium, fluorouracil, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 1,260 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Digestive System Neoplasm
Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
This phase I/II trial compares the effect of drugs that causes widening of blood vessels as a result of smooth muscle relaxation (vasodilator therapy) with isosorbide mononitrate, diltiazem or placebo to reduce vasotoxicity in…
- Trial name
- NCT07456852
- Testing
- Biospecimen Collection, Capecitabine, Diltiazem Hydrochloride
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
GC/GEJC
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
This study is a prospective, randomized ，multicencter, phase II clinical trial that aims to enroll patients with locally advanced gastric adenocarcinoma who have not received any prior treatment and are candidates for surgery.
- Trial name
- NCT06684158
- Testing
- Mecapegfilgrastim, Adebrelimab, Docetaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Nasopharyngeal Carcinoma, Nutritional Support
Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma
Radiation therapy remains the principal treatment for nasopharyngeal carcinoma (NPC). The most frequently occurred radiation-related side effect is probably the radiation-induced oral mucositis, which affects up to 100% of NPC…
- Trial name
- NCT03344068
- Testing
- Radiotherapy, Chemotherapy, Nutren® Optimum
- Where
- China
- Volunteers
- 408 people
- Sponsor
- Sun Yat-sen University
Rectal Neoplasms
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer
Standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-Fluorouracil (5-FU) plus 4 cycles of postoperative chemotherapy with 5-FU.
- Trial name
- NCT00349076
- Testing
- 5-FU and oxaliplatin, 5-FU
- Where
- 89 sites in Germany
- Volunteers
- 1,256 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Gastric Cancer
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS≥1
- Trial name
- NCT06793917
- Testing
- Tislelizumab, Oxaliplatin injection, Levo-Leucovorin
- Where
- China
- Volunteers
- 269 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer
The current standard treatment for locally advanced rectal cancer is still fluorouracil-based neoadjuvant radiotherapy and chemotherapy followed by TME surgery, followed by adjuvant chemotherapy.
- Trial name
- FANTASTIC (NCT04338191)
- Testing
- mFOLFOXIRI adjuvant chemotherapy, mFOLFOX6 adjuvant chemotherapy
- Where
- China
- Volunteers
- 638 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi chemotherapy plus targeted therapy); in both arms the…
- Trial name
- NCT01442935
- Testing
- Oxaliplatin, Folinic Acid, 5-FU
- Where
- France
- Volunteers
- 256 people
- Sponsor
- UNICANCER
Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
This phase Ib/II trial studies the side effects and best dose of pan fibroblast growth factor receptor (FGFR) kinase inhibitor BGJ398 when given together with fluorouracil, irinotecan hydrochloride and oxaliplatin (combination…
- Conditions
- Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02575508
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Hepatocellular Carcinoma
P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.
To evaluate the efficacy and safety of postoperative hepatic arterial infusion chemotherapy, interferon/fluorouracil versus low-dose cisplatin/fluorouracil, in patients with hepatocellular carcinoma with portal vein tumor…
- Trial name
- NCT01834963
- Testing
- Interferon Alfa、Fluorouracil, Cisplatin、Fluorouracil
- Where
- Japan
- Volunteers
- 66 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Esophageal Cancer
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (TPF) in Pre-treated patients…
- Trial name
- NCT00209716
- Testing
- Taxotere, 5-Fluorouracil, Briplatin
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Hokkaido Gastrointestinal Cancer Study Group
Pregnancy, Neonates
Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
The objective of follow-up study P05713 is to evaluate whether corifollitropin alfa (Org 36286) treatment for the induction of monofollicular growth in women who underwent ovulation induction (OI) in base study P05693…
- Trial name
- Care (NCT00702338)
- Testing
- corifollitropin alfa, recombinant Follicle Stimulating Hormone (recFSH), human Chorion Gonadotropin (hCG)
- Volunteers
- 1 people
- Sponsor
- Organon and Co
Gastric Cancer
Perioperative Chemotherapy in Gastric Cancer
Patients with resectable adenocarcinoma of stomach or esophagogastric junction without previous therapy will be treated with one of two chemotherapy regimens perioperatively.
- Trial name
- PECORINO (NCT04937738)
- Testing
- Docetaxel, Oxaliplatin, Leucovorin
- Where
- Ukraine
- Volunteers
- 69 people
- Sponsor
- Ukrainian Society of Clinical Oncology
Pancreatic Adenocarcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with…
- Trial name
- NCT03193190
- Testing
- Nab-Paclitaxel, Gemcitabine, Oxaliplatin
- Where
- 23 sites in United States, Germany and 3 more
- Volunteers
- 341 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.
- Trial name
- NCT01490866
- Testing
- Axitinib, Bevacizumab, 5-Fluorouracil
- Where
- 12 sites in United States
- Volunteers
- 70 people
- Sponsor
- SCRI Development Innovations, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.